Opinion

Video

Checkpoint Inhibitors for Treatment of NMIBC

Experts share their initial impressions of the available data on immunotherapies, including PD-L1 inhibitors durvalumab and sasanlimab, being evaluated in bacille Calmette-Guérin (BCG)–unresponsive patients with non–muscle-invasive bladder cancer (NMIBC).

Related Videos
1 expert in this video
3 experts are featured in this series.
3 experts are featured in this series.
1 expert in this video
Related Content
© 2025 MJH Life Sciences

All rights reserved.